TRAW vs. ADVM, IMAB, ENTX, GNTA, SCLX, SKYE, KPTI, CUE, GNLX, and BLUE
Should you be buying Traws Pharma stock or one of its competitors? The main competitors of Traws Pharma include Adverum Biotechnologies (ADVM), I-Mab (IMAB), Entera Bio (ENTX), Genenta Science (GNTA), Scilex (SCLX), Skye Bioscience (SKYE), Karyopharm Therapeutics (KPTI), Cue Biopharma (CUE), Genelux (GNLX), and bluebird bio (BLUE). These companies are all part of the "pharmaceutical products" industry.
Traws Pharma vs.
Adverum Biotechnologies (NASDAQ:ADVM) and Traws Pharma (NASDAQ:TRAW) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, dividends, media sentiment, profitability, analyst recommendations, community ranking, institutional ownership and risk.
Adverum Biotechnologies received 369 more outperform votes than Traws Pharma when rated by MarketBeat users.
Adverum Biotechnologies has a beta of 0.96, indicating that its stock price is 4% less volatile than the S&P 500. Comparatively, Traws Pharma has a beta of 1.13, indicating that its stock price is 13% more volatile than the S&P 500.
Adverum Biotechnologies presently has a consensus target price of $27.83, indicating a potential upside of 532.58%. Given Adverum Biotechnologies' stronger consensus rating and higher possible upside, analysts clearly believe Adverum Biotechnologies is more favorable than Traws Pharma.
In the previous week, Traws Pharma had 1 more articles in the media than Adverum Biotechnologies. MarketBeat recorded 1 mentions for Traws Pharma and 0 mentions for Adverum Biotechnologies. Traws Pharma's average media sentiment score of 0.59 beat Adverum Biotechnologies' score of 0.00 indicating that Traws Pharma is being referred to more favorably in the news media.
Traws Pharma has lower revenue, but higher earnings than Adverum Biotechnologies. Adverum Biotechnologies is trading at a lower price-to-earnings ratio than Traws Pharma, indicating that it is currently the more affordable of the two stocks.
48.2% of Adverum Biotechnologies shares are held by institutional investors. Comparatively, 7.9% of Traws Pharma shares are held by institutional investors. 4.2% of Adverum Biotechnologies shares are held by insiders. Comparatively, 16.1% of Traws Pharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Adverum Biotechnologies has a net margin of 0.00% compared to Traws Pharma's net margin of -62,294.25%. Traws Pharma's return on equity of 0.00% beat Adverum Biotechnologies' return on equity.
Summary
Adverum Biotechnologies beats Traws Pharma on 9 of the 17 factors compared between the two stocks.
Get Traws Pharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for TRAW and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Traws Pharma Competitors List
Related Companies and Tools
This page (NASDAQ:TRAW) was last updated on 1/21/2025 by MarketBeat.com Staff
Free TRAW Stock Alerts